GSK and Alfasigma Licensing Agreement, Servier's $2.5B Acquisition
Decision brief
Answer first · skim in under a minute
GSK and Alfasigma have entered a licensing agreement for Linerixibat, while Servier has finalized a $2.5 billion acquisition of Day One Pharmaceuticals. This article explores the implications for the pharmaceutical landscape.
Two mid-2026 deals reset rare-disease and rare-oncology portfolios: GSK licensed worldwide rights to Linerixibat (Lynavoy) to Alfasigma, and Servier completed its roughly $2.5 billion acquisition of Day One Biopharmaceuticals. Deal terms and closing dates are now public on company and SEC primary filings.
Contents10 sections
Key Takeaways
- GSK–Alfasigma linerixibat licence: $300M upfront, plus FDA/EU/UK approval milestones and up to $270M sales milestones, with tiered double-digit royalties (GSK, 9 March 2026).
- Linerixibat targets cholestatic pruritus in primary biliary cholangitis; filings cite GLISTEN Phase III data and multi-region regulatory review.
- Servier agreed to buy Day One for $21.50/share (~$2.5B equity value) on 6 March 2026 and closed the merger on 23 April 2026 (PR Newswire; SEC 8-K).
- Day One adds OJEMDA (tovorafenib) for pediatric low-grade glioma plus clinical-stage rare oncology assets to Servier.
What did GSK and Alfasigma agree on for Linerixibat?
On 9 March 2026, GSK and Alfasigma announced a licence giving Alfasigma worldwide exclusive rights to develop, manufacture, and commercialise linerixibat, an IBAT inhibitor for cholestatic pruritus in PBC.
GSK is to receive $300 million upfront, $100 million upon U.S. FDA approval (PDUFA target cited as 24 March 2026 in the announcement), $20 million upon EU and UK approval, up to $270 million in sales-based milestones, and tiered double-digit royalties on net sales.
How large is Servier’s Day One acquisition?
On 6 March 2026, Servier and Day One announced a definitive agreement for Servier to acquire Day One at $21.50 per share in cash, a total equity value of about $2.5 billion, per PR Newswire and Day One’s SEC exhibits.
Servier reported closing on 23 April 2026 after the tender offer and Section 251(h) merger. The Day One Form 8-K states aggregate consideration of approximately $2.5 billion in equity value.
What assets transfer with Day One?
Closing materials highlight OJEMDA (tovorafenib), FDA-approved in pediatric low-grade glioma in the U.S., with ex-U.S. rights licensed to Ipsen. Pipeline add-ons named in the completion release include Emi-Le (emiltatug ledadotin) and DAY301.
- $21.50 cash per Day One share
- ~$2.5B equity value
- Close date: 23 April 2026
Why these deals matter for BD teams
The linerixibat licence crystallises late-stage GI/rare-liver value without GSK retaining commercial rights. Servier’s cash buy of a marketed rare-oncology name shows foundation-owned buyers still paying mid-single-digit-billion premiums for focused portfolios.
What remains unproven?
GSK’s March release stated linerixibat was not yet approved anywhere at announcement; subsequent Q1 2026 GSK materials note the Alfasigma licence closed 22 April 2026. Independent confirmation of post-close sales milestones and EU/UK approval timing still depends on future regulator actions.
How should investors track next catalysts?
Watch Alfasigma commercial launch plans for Lynavoy/linerixibat after regional approvals, and Servier integration updates for OJEMDA U.S. sales plus pipeline progression of Emi-Le and DAY301. Cross-check future SEC filings and wire releases rather than secondary deal roundups.
Related NovaPharma coverage
Frequently Asked Questions
What is Linerixibat licensed for?
Linerixibat is an IBAT inhibitor licensed by GSK to Alfasigma for cholestatic pruritus associated with primary biliary cholangitis, based on GLISTEN Phase III data cited in GSK’s 9 March 2026 announcement.
How much did Servier pay for Day One?
Servier paid $21.50 per share in cash, representing about $2.5 billion in equity value, and completed the acquisition on 23 April 2026.
When did the GSK–Alfasigma linerixibat deal close?
GSK’s Q1 2026 materials state the licence agreement under which Alfasigma acquired worldwide exclusive rights closed on 22 April 2026.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Linerixibat.
Unlock full calendar →GSK pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
